Rare Events, Rare Disease: “Theoretical” Issues Central To FDA Soliris Review
Executive Summary
The effect of Alexion's paroxysmal nocturnal hemoglobinuria therapy Soliris (eculizumab) on thrombosis, a major clinical problem associated with the rare blood disorder, was one of the most contested issues in the review of the Soliris BLA, FDA review documents suggest
You may also be interested in...
Alexion’s Soliris Blood Treatment Will Cost Almost $400,000 Per Year
Alexion Pharmaceuticals is launching its paroxysmal nocturnal hemoglubinuria Soliris (eculizumab) with a treatment support service with case managers to help facilitate reimbursement
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.